Literature DB >> 25957287

A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.

Daniela F Angelini1, Tiziana Ottone2, Gisella Guerrera1, Serena Lavorgna2, Michela Cittadini2, Francesco Buccisano3, Marco De Bardi1, Francesca Gargano1, Luca Maurillo3, Mariadomenica Divona3, Nélida I Noguera4, Maria Irno Consalvo3, Giovanna Borsellino1, Giorgio Bernardi5, Sergio Amadori3, Adriano Venditti3, Luca Battistini1, Francesco Lo-Coco6.   

Abstract

PURPOSE: We evaluated leukemia-associated immunophenotypes (LAIP) and their correlation with fms-like tyrosine kinase 3 (FLT3) and nucleophosmin (NPM1) gene mutational status in order to contribute a better identification of patients at highest risk of relapse in acute myeloid leukemia (AML). EXPERIMENTAL
DESIGN: Bone marrow samples from 132 patients with AML were analyzed by nine-color multiparametric flow cytometry. We confirmed the presence of the mutation in diagnostic samples and in sorted cells by conventional RT-PCR and by patient-specific RQ-PCR.
RESULTS: Within the CD34(+) cell fraction, we identified a discrete population expressing high levels of the IL3 receptor α-chain (CD123) and MIC-2 (CD99) in combination with the IL2 receptor α-chain (CD25). The presence of this population positively correlated with the internal tandem duplications (ITD) mutation in the FLT3 gene (r = 0.71). Receiver operating characteristics showed that, within the CD34(+) cell fraction a percentage of CD123/CD99/CD25(+) cells ≥11.7% predicted FLT3-ITD mutations with a specificity and sensitivity of >90%. CD34/CD123/CD99/CD25(+) clones were also detectable at presentation in 3 patients with FLT3 wild-type/NPM1(+) AML who relapsed with FLT3-ITD/NPM1(+) AML. Quantitative real-time PCR designed at relapse for each FLT3-ITD in these three cases confirmed the presence of low copy numbers of the mutation in diagnostic samples.
CONCLUSIONS: Our results suggest that the CD34/CD25/CD123/CD99(+) LAIP is strictly associated with FLT3-ITD-positive cells. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25957287     DOI: 10.1158/1078-0432.CCR-14-3186

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  29 in total

1.  CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.

Authors:  John N Allan; Gail J Roboz; Gulce Askin; Ellen Ritchie; Joseph Scandura; Paul Christos; Duane C Hassane; Monica L Guzman
Journal:  Leuk Lymphoma       Date:  2017-07-18

2.  Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.

Authors:  Lina Han; Jeffrey L Jorgensen; Chris Brooks; Ce Shi; Qi Zhang; Graciela M Nogueras González; Antonio Cavazos; Rongqing Pan; Hong Mu; Sa A Wang; Jin Zhou; Gheath Ai-Atrash; Stefan O Ciurea; Mike Rettig; John F DiPersio; Jorge Cortes; Xuelin Huang; Hagop M Kantarjian; Michael Andreeff; Farhad Ravandi; Marina Konopleva
Journal:  Clin Cancer Res       Date:  2017-01-17       Impact factor: 12.531

3.  A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.

Authors:  Yelena Kovtun; Gregory E Jones; Sharlene Adams; Lauren Harvey; Charlene A Audette; Alan Wilhelm; Chen Bai; Lingyun Rui; Rassol Laleau; Fenghua Liu; Olga Ab; Yulius Setiady; Nicholas C Yoder; Victor S Goldmacher; Ravi V J Chari; Jan Pinkas; Thomas Chittenden
Journal:  Blood Adv       Date:  2018-04-24

4.  CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Authors:  Adam J Lamble; Lisa Eidenschink Brodersen; Todd A Alonzo; Jim Wang; Laura Pardo; Lillian Sung; Todd M Cooper; E Anders Kolb; Richard Aplenc; Sarah K Tasian; Michael R Loken; Soheil Meshinchi
Journal:  J Clin Oncol       Date:  2021-12-02       Impact factor: 44.544

Review 5.  CD99 in malignant hematopoiesis.

Authors:  Atham Ali; Vijaya Pooja Vaikari; Houda Alachkar
Journal:  Exp Hematol       Date:  2021-12-14       Impact factor: 3.249

Review 6.  Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches.

Authors:  Deepshi Thakral; Ritu Gupta; Aafreen Khan
Journal:  Stem Cell Rev Rep       Date:  2022-03-28       Impact factor: 6.692

Review 7.  Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.

Authors:  Maria Ilaria Del Principe; Francesco Buccisano; Luca Maurillo; Giuseppe Sconocchia; Mariagiovanna Cefalo; Maria Irno Consalvo; Chiara Sarlo; Consuelo Conti; Giovanna De Santis; Eleonora De Bellis; Ambra Di Veroli; Patrizia Palomba; Cristina Attrotto; Annagiulia Zizzari; Giovangiacinto Paterno; Maria Teresa Voso; Giovanni Del Poeta; Francesco Lo-Coco; William Arcese; Sergio Amadori; Adriano Venditti
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-20       Impact factor: 2.576

Review 8.  CD99: A Cell Surface Protein with an Oncojanus Role in Tumors.

Authors:  Maria Cristina Manara; Michela Pasello; Katia Scotlandi
Journal:  Genes (Basel)       Date:  2018-03-13       Impact factor: 4.096

9.  Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.

Authors:  Adhra Al-Mawali; David Gillis; Ian Lewis
Journal:  J Hematol Oncol       Date:  2016-07-27       Impact factor: 17.388

10.  Adaptive immunity-related gene expression profile is correlated with clinical phenotype in patients with acute myeloid leukemia.

Authors:  Peng Chen; Yi Liu; Rui Zhang; Haitao Wang; Juan Zhang; Meng Guo; Zhenlan Du
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.